Group Health has both elements and Franc beautiful pre-announced by a notice to benefit from the main business and investment income growth, health yuan mid-year report net profit increased 250% pre-; and Franc group also pre-announced mid-year report net profit growth 200% to 250%. Yesterday afternoon, the two companies led by Chairman Zhu Baoguo network executives held in Panorama exchange investors, corporate governance, this is the first merger between a controlled meeting. healthy 43.8 million held by Franc % of the shares, the stock linkage between the two companies is growing. Zhu Baoguo expressed during the health element to complete private placement will be the most important task in the second half, while no clear reduction in the secondary market Livzon shares.
accelerated in the second half both 2007 in Jiaozuo 7ACA (cephradine intermediate) project was put into trial production at the same time and Cabernet Franc Cephradine antibiotics business to form industrial chain advantage;'s Haibin Pharmaceutical in 1998 to develop and pilot a successful meropenem agents have been developed to fight program into the European and American markets, COS certification is currently being prepared, the preparation times to the present about to enter the Belarusian market; all rely on the original Japanese import imipenem intermediate 4AA, has now grown; Haibin Pharmaceutical future will become the world's largest carbon penicillin production base.
started to health care products is beginning to speed up the transformation of health yuan, said Zhu Baoguo the future health of the three main growth element is put into operation this year for drug 7ACA; mainly concentrated in the areas of new prescription drugs marketed products, including the digestive system classes, such as antibiotics and reproductive system of products with independent intellectual property rights; and still apply for a license innovative health care products direct sales model.
Franc Everbright Group's anti-virus particles in the pharmaceutical January 30, 2007 Laboratory of Microbiology, University of Hong Kong was officially confirmed on highly pathogenic H5N1 avian influenza virus propagation in vivo and to spread outside the respiratory tract are inhibited. Shenqifuzheng injection treatment of coronary heart disease through clinical trials, expected in 2008 will be used in two major areas of cancer and cardiovascular; Li Fukang (voriconazole - the most advanced anti-fungal) a new generation of broad-spectrum antifungal upcoming; Franc North River under the holding of new pharmaceuticals, lovastatin production line has been certified by the U.S. FDA.
shares, the second phase of construction for 7ACA. The company has made it clear, additional objects from many indications, there is likely to be entered in the foreign pharmaceutical giants. It has become the most concern to investors yesterday.
In this regard, Zhu Baoguo clear that such as industrial capital, but taking into account a matter of time, may advance the introduction of a number of investment funds.
has investors asking, Deputy General Manager of Qiu Qingfeng responded, who in exchange for advanced technology, do not worry so much about loss of control of development opportunities. Zhu Baoguo said, the time of the company before the introduction of foreign advanced technology to, you can look at the domestic joint-venture pharmaceutical companies to clear, never savior, only on their own. As long as the development of real pro-business, I will not mind control. , but not through the secondary market, he said the Group's equity holdings Franc.
Qiu Qingfeng also revealed that health yuan 737.55 million shares held by Shandong Haihua has been a substantial reduction in the future health of dollars will change its stock price little effect on performance, but as a small non-Topsun Science and Technology (holds 660 million shares) of the current reduction plans not yet clear.
recently launched in the second half of the securities Shun 10-Daikin shares, ranking the health element the first place.
No comments:
Post a Comment